Stocksigma LogoStocksigma Logo

Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement

Biocon Limited has entered into a licensing agreement with Janssen Sciences Ireland, enabling immediate commercialization rights for Yesintek (a proposed

Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement

Biocon Ltd 路 Others (Uncategorized) 路 26 Oct 2026, 1:57 pm

Biocon Secures Global Market Entry for Biosimilar Yesintek Through Janssen Licensing Agreement Biocon Limited has entered into a licensing agreement with Janssen Sciences Ireland, enabling immediate commercialization rights for Yesintek (a proposed biosimilar to Ustekinumab / Stelara) across Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan, subject to regulatory approvals. This expands upon prior agreements covering the US, Europe, UK, Canada, and Japan. Yesintek targets autoimmune indications including Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Reference drug Stelara recorded global sales of $6.08 billion in 2025.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements